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Abstract: Aluminum is a common contaminant in many components of parenteral nutrition,
especially calcium and phosphate additives. Although long-term effects have been described in
the literature, short-term effects are not well-known. Currently, the Food and Drug Administration
recommends maintaining aluminum at <5 mcg/kg/day. This was a single center, retrospective
case-control study of 102 neonatal intensive care unit patients. Patients were included if they had a
diagnosis of necrotizing enterocolitis, rickets/osteopenia, or seizures and received at least 14 days
of parenteral nutrition. Patients were matched 1:1 with control patients by gestational age and
birth weight. Mean total aluminum exposure for the 14 days of parenteral nutrition was calculated
using manufacturer label information. Differences in mean aluminum exposure between cases and
controls, as well as subgroup analysis in those with renal impairment or cholestasis, was conducted.
Aluminum exposure in patients meeting inclusion criteria closely mirrored the aluminum exposure
of control patients. The difference in aluminum exposure was not found to be statistically significant,
except in patients with cholestasis. Although the study found no difference in aluminum exposure
in short-term complications with neonates, long-term complications are well established and may
warrant the need to monitor and limit neonatal aluminum exposure.
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1. Introduction
Aluminum serves no known biological role in the human body. Humans are naturally exposed
to aluminum through drinking water, foods, medications, dust, and deodorant [1]. Additionally,
aluminum is a common contaminant in many components of parenteral nutrition, especially calcium
and phosphate additives. Under normal circumstances, the human body has natural defense
mechanisms that prevent significant absorption of ingested aluminum. An intact gastrointestinal
tract typically allows less than 1% absorption of aluminum [1]. Of the aluminum that enters the
bloodstream, 99% is excreted through the kidneys.
Preterm infants require high amounts of calcium and phosphate for bone mineralization.
This, coupled with poor renal function, predispose preterm infants to a high risk for aluminum toxicity
when fed parenterally. Reports of aluminum toxicity have been described since the 1970s [2]. Potential
long-term effects of aluminum include neurotoxicity, anemia, bone disease, and cholestasis [3–12].
As such, the Food and Drug Administration recommends maintaining aluminum exposure at less than
5 mcg/kg/day [13].
Currently, there is little research examining the effects of parenteral aluminum exposure on
neonatal morbidities in an acute inpatient setting. The objective of this study was to determine if
estimated mean cumulative aluminum exposure as part of parenteral nutrition is increased in neonates
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with poor outcomes, including necrotizing enterocolitis, rickets/osteopenia, and/or seizures when
compared with control patients. Diagnoses were selected based on previous literature establishing
a relationship between aluminum exposure and development of neurotoxicity and inhibition of
proper bone maturation [3–12,14]. Necrotizing enterocolitis was selected as an inclusion diagnosis
based on the direct relationship of the disease state with extended parenteral nutrition requirements.
Secondary outcomes included: evaluation of mean cumulative aluminum exposure in neonates with
renal dysfunction or cholestasis as well as determination of the doses of aluminum to which more
cases were exposed, if a significant difference existed between cases and controls.
2. Materials and Methods
2.1. Study Design
This was a single center, retrospective, case-control study. All data was collected utilizing
electronic medical records. Data collected included: gestational age, birth weight, daily weight,
diagnoses, and parenteral nutrition (PN) formulas. Parenteral nutritional formulas, as well as daily
weight, were entered into an aluminum calculator developed by investigators in Microsoft Excel©
(Microsoft Professional Office 2016; Microsoft Corporation, Redmond, WA, USA) utilizing current
manufacturer labeling to determine daily exposure to aluminum in mcg/kg/day (Table 1).
Table 1. Manufacturer Aluminum Content.
Product Brand Aluminum Content (mcg/L)
Dextrose Hospira 25
Amino Acids Hospira 25
Sodium Chloride APP/Fresenius 1 200
Sodium Acetate APP/Fresenius 400
Sodium Phosphate APP/Fresenius 16,000
Potassium Chloride APP/Fresenius or Hospira 100
Potassium Acetate Exela or Hospira 200
Potassium Phosphate APP/Fresenius 32,800
Calcium Gluconate American Regent 12,500
Magnesium Sulfate American Regent 12,500
Fat Emulsion APP/Fresenius 25
1 APP-American Pharmaceutical Partners.
Each PN formula was entered into the calculator by the primary investigator. Daily aluminum
exposure over the first 14 days in each patient were added to determine the cumulative aluminum
exposure in mcg/kg. Data was maintained utilizing a de-identified list. This study was approved by
the Wichita Medical Research and Education Foundation Institutional Review Board.
2.2. Patient Selection
Patients were included in the study sample if they received at least 14 days of parenteral nutrition
between 1 June 2013 and 30 June 2016. All patients who received 14 days of parenteral nutrition
during the preselected timeframe were retrieved from the electronic database. From there, cases were
selected if they had a diagnosis consistent with necrotizing enterocolitis, rickets/osteopenia, or seizures
based on diagnoses in Neodata® (Isoprime, Lisle, IL, USA). Control patients were selected if they had
received at least 14 days of parenteral nutrition without development of any of the inclusion diagnoses.
Controls were selected using a random sequence generator. Cases were matched 1:1 to a control patient
based on gestational age and birth weight. Patients were excluded if they were diagnosed with any
inclusion diagnoses prior to the initiation of parenteral nutrition, if they received less than 14 days of
parenteral nutrition, or if they were small for gestational age. There were no gestational age or birth
weight requirements for inclusion in the study.
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2.3. Outcomes
The primary outcome of this study was to determine if estimated mean cumulative aluminum
exposure as part of parenteral nutrition is increased in neonates with poor outcomes, including
necrotizing enterocolitis, rickets/osteopenia, and/or seizures. Secondarily, the study aimed to evaluate
the mean cumulative aluminum exposure in neonates with renal dysfunction, defined as serum
creatinine >1.5 mg/dL, or cholestasis, defined as direct bilirubin >2 mg/dL. An additional secondary
outcome included determining the doses of aluminum (mcg/kg/day) to which more cases were
exposed, if a significant difference in exposure existed between cases and controls.
2.4. Statistical Analysis
Based on an alpha of 5% and an 80% power to detect a difference in risk of development of
inclusion diagnoses between cases and control of approximately 2.5 (i.e., odds ratio = 2.5), we calculated
that 85 cases and 85 controls need to be included [14,15]. Differences in mean aluminum exposure
between cases and controls were analyzed using a Student’s t-test. If a statistically significant difference
(p < 0.05) in aluminum exposure was found between cases and controls, a classification and regression
tree (CART) analysis would be conducted to determine the doses of aluminum for which more cases
were exposed.
3. Results
A total of 156 patients were selected between 1 June 2013 and 30 June 2016. Of these, 54 patients
were excluded due to receiving less than 14 days of parenteral nutrition. The remaining 102 resulted in
51 matched pairs. There was an even split of male and female patients with 51 of each. Patients were
on average 27 weeks and 3 days gestational age (24 weeks, 2 days–33 weeks, 6 days) and weighed
1.029 kg (0.59 kg–2.223 kg) at birth. Thirty-one patients had a diagnosis of seizures, nineteen patients
had a diagnosis of necrotizing enterocolitis, and twenty-three patients had osteopenia/rickets. Of the
patients included, twenty had at least two inclusion diagnoses and two patients met all three inclusion
diagnoses. Regarding secondary endpoints, ten patients met inclusion criteria for renal dysfunction
and three patients met criteria for cholestasis. Demographic information can be found in Table 2.
Table 2. Patient Demographic Data.
Case Patients (n = 51) Control Patients (n = 51)
Average Gestational Age 27 weeks, 2 days (±1 week, 3 days) 27 weeks, 3 days (±1 week, 3 days)
Average Birth Weight 1.029 kg (±0.32 kg) 1.029 kg (±0.32 kg)
Gender, male 27 (53%) 24 (47%)
Seizures 31 diagnoses (61%) -
Necrotizing Enterocolitis 19 diagnoses (19%) -
Osteopenia/Rickets 23 diagnoses (45% -
Total aluminum exposure in all patients meeting inclusion criteria was 78.8 mcg/kg/day when
compared with control patients of 79.2 mcg/kg/day (p = 0.87). Patients with a diagnosis of seizures
had a total aluminum exposure of 78.3 mcg/kg/day when compared with control patients of
78.7 mcg/kg/day (p = 0.91). Regarding necrotizing enterocolitis, patients with the diagnosis had
a 79.1 mcg/kg/day while matched control patients had a total exposure of 80.5 mcg/kg/day (p = 0.72).
Total aluminum exposure in patients with osteopenia or rickets was 80.8 mcg/kg/day when compared
with controlled patients whose aluminum exposure was 79.6 mcg/kg/day (p = 0.76). Twenty patients
had multiple inclusion diagnoses. The total aluminum exposure of case patients who had multiple
inclusion diagnoses was 80.1 mcg/kg/day versus average 78.6 mcg/kg/day (p = 0.75).
A total of 10 patients met the inclusion criteria for renal dysfunction. The average aluminum exposure
of these 10 patients was 80.4 mcg/kg/day when compared with 78.9 mcg/kg/day in the 92 patients
who did not have renal dysfunction (p = 0.7). Three patients met the inclusion criteria for cholestasis.
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The average aluminum exposure in patients with cholestasis was 91.7 mcg/kg/day compared with
78.7 mcg/kg/day in the 99 patients who did not meet inclusion criteria for cholestasis (p = 0.04).
4. Discussion
The utilization of parenteral nutrition (PN) is a routine practice in the neonatal intensive care
unit. Aluminum is commonly found as a contaminant in many components of parenteral nutrition,
especially calcium and phosphate additives. A study conducted by Moreno and colleagues, found that
parenteral nutrition solutions were the main source of aluminum exposure in neonates, representing
88.7% of aluminum intake [16]. Reports of aluminum toxicity first appeared in the 1970’s [3]. However,
to our knowledge this is the first study to assessing the relationship between aluminum exposure
through parenteral nutrition and acute morbidities in neonatal patients.
An influential study published by Bishop and colleagues examined 227 infants in the
neonatal intensive care unit. The infants were randomized to receive either standard aluminum
or aluminum-depleted intravenous-feeding solutions. In infants who received more than 10 days of
parenteral nutrition, the Mental Development Index of those receiving the standard aluminum PN was
found to be statistically lower than those who received the aluminum-depleted intravenous-feeding
solutions (p = 0.02). In addition, infants who received the standard aluminum intravenous-feeding
solutions were statistically more likely to have a Mental Development Index below 85 points,
which could increase their risk of educational impairment (p = 0.03). It was estimated that infants
would lose around one Mental Development Index point for each day on the standard aluminum
solution [4]. However, it is important to note that infants with a diagnosis of neuromotor impairment
were excluded as this impairment could render the assessment of the Bayley Mental Scale inaccurate.
A follow-up study by Fewtrell and colleagues evaluated what effect the standard aluminum and
aluminum-depleted intravenous-feeding solutions had on the bone development of infants from the
Bishop study. Adolescents who had participated in the Bishop study as infants were invited back
for assessment of bone area, bone mineral content, and bone mineral density. Patients who had a
high exposure to aluminum (55 mcg/kg/day) had significantly lower hip bone mineral content after
adjusting for confounding variables (p = 0.02) [12].
In addition, the rate of parenteral nutrition-associated cholestasis ranges from 7.4% to 84% [2].
Previous research has shown that hepatic aluminum concentrations were between 5 and 27 times
higher than normal concentrations in infants receiving parenteral nutrition [17]. Further studies in
animals found that animals who were exposed to parenteral nutrition had significant increases in
both the serum bile acids and alkaline phosphatase levels when compared with animals who had not
received parenteral nutrition [18,19]. Rats who had received parenteral nutrition for 14 days had higher
concentrations of serum bile acids than those who had received parenteral nutrition for 7 days [19].
Of the rats who received the parenteral nutrition for 14 days, the group that received high doses of
aluminum (5 mg/kg/day) had a 33% reduction in biliary flow [19].
A previous study demonstrated that approximately 90% of pediatric patients between the ages
of 6 months and 17 years receiving parenteral nutrition had plasma aluminum concentrations above
the reference range of 0–371 mmol/L [20]. Of these patients, approximately 20% of patients had an
aluminum concentration 5–8 times the upper limit of normal [20]. Due to the retrospective nature of this
study, aluminum exposure was calculated versus drawn serum levels. A previous study showed that
there is no difference in aluminum serum concentrations with various levels of aluminum exposure [21].
However, at our institution serum aluminum levels are not routinely drawn, limiting our ability to
evaluate true total aluminum exposure.
For consistency within our study, the aluminum content listed by the manufacturer was used to
build the aluminum calculator. However, in 2012 Poole and colleagues demonstrated that components of
parenteral nutrition may contain less aluminum than labeled by the manufacturer [22]. Despite finding
that parenteral nutrition components contained less aluminum than the label indicated, Poole and
colleagues identified that neonatal compounded parenteral nutrition still contained 3–5 times more than
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the United States Food and Drug Administration (FDA) recommended “safe limit.” The study concluded
that even when making a conscious effort to use the least contaminated parenteral nutrition products,
daily aluminum exposure still totaled to 8.8–12.9 mcg/kg/day [22]. Notably, the highest measured and
calculated aluminum content was found among the smallest patients.
Despite literature describing the complications associated with aluminum exposure, our study
supports previous claims of the inability to provide nutrition and maintain aluminum exposure less
than 5 mcg/kg/day. In fact, of the 1428 parenteral nutrition formulas analyzed during the study
period, only seven formulas contained aluminum in amounts below the FDA “safe limit.” However,
in spite of providing aluminum beyond the FDA limit in the majority of our patients, mean cumulative
aluminum exposures were similar in those with and without the outcomes of interest. There were a
few limitations with our study. In some instances, the neonates involved in our study did not receive
all 14 of their PN days consecutively. In addition, only the first 14 days of parenteral nutrition was
evaluated, so it is possible the total cumulative aluminum exposure may differ between patients with
diagnoses versus control patients if patients with inclusion diagnoses had received more total days of
parenteral nutrition. Other limitations of this study include that patients were only matched on weight
and gestational age, which may not account for all compounding factors. Specific amounts of calcium
and phosphate were not evaluated in related to osteopenia/rickets diagnoses. Finally, the study fell
short of enrolling enough patients to meet predefined power.
5. Conclusions
In conclusion, mean cumulative aluminum exposure in neonates receiving at least 14 days of
parenteral nutrition was similar among those with and without necrotizing enterocolitis, seizures, and/or
osteopenia/rickets. The majority of patients were exposed to aluminum concentrations above the current
FDA limit. However, larger, high-quality studies are needed to further assess the relationship between
aluminum exposure and morbidity.
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